Two Sigma Advisers LP acquired a new position in shares of Editas Medicine (NASDAQ:EDIT) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 26,500 shares of the company’s stock, valued at approximately $814,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Wells Fargo & Company MN increased its holdings in Editas Medicine by 7.5% during the 4th quarter. Wells Fargo & Company MN now owns 48,791 shares of the company’s stock worth $1,500,000 after purchasing an additional 3,415 shares during the period. Great West Life Assurance Co. Can increased its holdings in Editas Medicine by 519.9% during the 3rd quarter. Great West Life Assurance Co. Can now owns 4,959 shares of the company’s stock worth $114,000 after purchasing an additional 4,159 shares during the period. Swiss National Bank increased its holdings in Editas Medicine by 11.7% during the 4th quarter. Swiss National Bank now owns 44,800 shares of the company’s stock worth $1,377,000 after purchasing an additional 4,700 shares during the period. Allianz Asset Management GmbH increased its holdings in Editas Medicine by 3.6% during the 4th quarter. Allianz Asset Management GmbH now owns 140,820 shares of the company’s stock worth $4,328,000 after purchasing an additional 4,915 shares during the period. Finally, Victory Capital Management Inc. increased its holdings in Editas Medicine by 12.4% during the 4th quarter. Victory Capital Management Inc. now owns 44,732 shares of the company’s stock worth $1,375,000 after purchasing an additional 4,920 shares during the period. Institutional investors own 65.36% of the company’s stock.

How to Become a New Pot Stock Millionaire

In other news, insider Katrine Bosley sold 3,338 shares of Editas Medicine stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $35.28, for a total value of $117,764.64. Following the transaction, the insider now directly owns 1,364,431 shares in the company, valued at approximately $48,137,125.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew A. F. Hack sold 40,000 shares of Editas Medicine stock in a transaction on Tuesday, March 20th. The shares were sold at an average price of $38.06, for a total value of $1,522,400.00. Following the completion of the transaction, the chief financial officer now owns 6,000 shares in the company, valued at $228,360. The disclosure for this sale can be found here. Insiders sold a total of 121,471 shares of company stock worth $4,546,487 over the last quarter. Company insiders own 19.40% of the company’s stock.

Several research analysts have commented on the company. Zacks Investment Research upgraded Editas Medicine from a “sell” rating to a “hold” rating in a report on Friday, March 9th. Barclays raised their price objective on Editas Medicine from $28.00 to $46.00 and gave the stock an “overweight” rating in a report on Wednesday, March 7th. Morgan Stanley restated an “equal weight” rating and set a $43.00 price objective (up from $28.00) on shares of Editas Medicine in a report on Wednesday, March 14th. BidaskClub upgraded Editas Medicine from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 30th. Finally, JMP Securities raised their price objective on Editas Medicine from $40.00 to $67.00 and gave the stock an “outperform” rating in a report on Wednesday, March 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating to the stock. Editas Medicine has a consensus rating of “Hold” and an average target price of $42.17.

Shares of NASDAQ:EDIT opened at $34.46 on Tuesday. Editas Medicine has a 12-month low of $13.12 and a 12-month high of $45.02. The company has a quick ratio of 9.05, a current ratio of 9.05 and a debt-to-equity ratio of 0.16.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Tuesday, March 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.09). Editas Medicine had a negative net margin of 876.49% and a negative return on equity of 61.92%. The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $4.25 million. During the same quarter in the prior year, the business posted ($1.10) earnings per share. The company’s revenue was up 311.1% compared to the same quarter last year. research analysts anticipate that Editas Medicine will post -3.3 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/04/17/two-sigma-advisers-lp-invests-814000-in-editas-medicine-edit-stock.html.

Editas Medicine Company Profile

Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine (NASDAQ:EDIT).

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.